Artwork
iconShare
 
Manage episode 518947607 series 3698093
Content provided by RetinUp Podcast, LLC, RetinUp Podcast, and LLC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by RetinUp Podcast, LLC, RetinUp Podcast, and LLC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

RetinUp – Episode 3: Shutdown’s Effects on FDA ft. Alec Gaffney from POLITICO | Plus, PRIMA Implant + GLP-1 Data Dump

Hosts:

John Kitchens, MD

Scott Krzywonos

Guest:

Alexander Gaffney, VP of Regulatory Policy & Intelligence, Agency IQ / POLITICO

Show Summary:

In this episode, Scott calls in from the Outer Banks to discuss two major clinical headlines before turning to federal policy. First up is the PRIMA retinal prosthesis, a wireless subretinal chip that helped patients with geographic atrophy regain partial reading vision. Then, Scott and John analyze the rapidly expanding — and often contradictory — body of research on GLP-1 receptor agonists and their links to retinal disease.

In the second half, they welcome Alexander Gaffney from POLITICO’s Agency IQ for a deep dive into how the ongoing government shutdown and widespread staff reductions are affecting the FDA’s ability to review and approve ophthalmic therapies. From PDUFA carry-over funds to workforce attrition, Alec explains why the true impact may not be the shutdown itself, but the backlog that follows.

Topics Covered:

  • PRIMA retinal implant: wireless innovation and its surgical challenges
  • The trade-off between functional vision gains and expanded atrophy area
  • GLP-1 receptor agonists: mixed data on AMD, DR, and DME risk
  • FDA shutdown implications for ophthalmic trials and approvals
  • The reduction in force across FDA divisions and its effect on review capacity
  • How new leadership and the National Priority Voucher Program aim to modernize the agency
  • Why backlogs could extend into 2026 for gene therapy and TKI programs

Key Quotes:

  • “I’m less worried about the shutdown itself — I’m worried about what happens afterward.”Alexander Gaffney
  • “You might not be able to read or drive, but that peripheral vision is what lets you move through the world. Losing more of that matters.”John Kitchens, MD
  • “We don’t always know what we’ve lost — how much faster certain drugs might have reached patients.”Scott Krzywonos

Credits:

Production & Marketing: Laura Brown

Business Operations: Liz Hogan

Listen and Subscribe:

RetinUp.com | Available on Apple Podcasts, Spotify, and YouTube

  continue reading

4 episodes